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The current recommendations for the treatment of obese people include increased physical activity and reduced calories intake. 
When the behavioral approach is not sufficient, a pharmacologic treatment is recommended. In past years, numerous drugs have 
been approved for the treatment of obesity; however, most of them have been withdrawn from the market because of their adverse 
effects. In fact, amphetamine, rimonabant and sibutramine licenses have been withdrawn due to an increased risk of psychiatric 
disorders and non-fatal myocardial infarction or stroke. Even if orlistat is not as effective as other drugs in reducing body weight, 
orlistat is presently the only available choice for the treatment of obesity because of its safety for cardiovascular events and posi-
tive effects on diabetic control. Hopefully, more effective and better tolerated anti-obesity drugs will be developed through an 
improved understanding of the multiple mechanisms and complex physiological systems targeting appetite.
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INTRODUCTION 
Obesity is now a global problem [1] and is associated with a 
number of chronic conditions including osteoarthritis, ob-
structive sleep apnea, gallstones, fatty liver disease, reproduc-
tive and gastrointestinal cancers, dyslipidemia, hypertension, 
type 2 diabetes, heart failure, coronary artery disease, and 
stroke [2,3]. Lifestyle modifications such as diet and exercise 
intervention are essential for both prevention and manage-
ment of obesity, and pharmacotherapy may be considered if 
the interventions are ineffective for individuals with a body 
mass index [BMI] ≥30 kg/m
2 or for those with a BMI ≥27 kg/
m
2 when co-morbidities, such as hypertension or type 2 dia-
betes mellitus are present [4]. However, anti-obesity drugs are 
a frequent adjunct, because these interventions have limited 
long-term success [5] and the weight is regained when treat-
ment is discontinued.
  Many medications have been used to manage obesity over 
the years. However, most of the anti-obesity drugs that were 
approved and marketed have now been withdrawn due to se-
rious adverse effects. In the 1990s, fenfluramine and dexfen-
fluramine were withdrawn from the market because of heart 
valve damage [6]. In 2000, the European Medicines Agency 
(EMA) recommended the market withdrawal of several anti-
obesity drugs, including phentermine, diethylpropion, and 
mazindol, due to an unfavorable risk to benefit ratio [7]. The 
first selective CB1 receptor blocker, rimonabant, was available 
in 56 countries from 2006 but was never approved by the U.S. 
Food and Drug Administration (FDA) due to an increased 
risk of psychiatric adverse events, including depression, anxi-
ety, and suicidal ideation [8]. Subsequently, rimonabant was 
withdrawn from the European market in 2009 (Table 1).
  Recently, many newer agents have been tried, though only 
orlistat and sibutramine have been approved for long-term 
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use. In October 2010, sibutramine, widely used after approval 
by the U.S. FDA in 1997, was withdrawn from the market be-
cause of an association with increased cardiovascular events 
and strokes [11], leaving only orlistat (Table 2). More recently, 
in February 2011, the U.S. FDA rejected approval of the bu-
propion/naltrexone combination marketed as Contrave due to 
concerns over potential cardiovascular risks. The long-term 
safety and efficacy of newly-developed drugs should also be 
Table 1. Anti-obesity medications withdrawn
Drug Introduced Mechanism FDA status
Fenfluramine 1973-U.S. Sympathomimetic amine (appetite suppression) Withdrawn 1997: valvular heart disease, pulmonary 
hypertension
Dexfenfluramine 1996-U.S. As above Withdrawn 1997: valvular heart disease, pulmonary 
hypertension
Rimonabant 2006-Europe Selective CB1 receptor blocker Not approved in U.S.: concern over psychiatric side 
effects
Withdrawn 2009: potential of serious psychiatric 
disorders
Temporarily withdrawn 2002
Sibutramine 1997-U.S. 
2001-Europe
Selective combined serotonin and noradrenaline 
reuptake inhibitor (appetite suppression)
Withdrawn 2010: increased risk of heart attack and 
stroke in high-risk cardiac patients
Modified from Powell et al. Clin Pharmacol Ther 2011;90:40-51 [9] and Ioannides-Demos et al. Drug Saf 2006;29:277-302 [10].
The drug (rimonabant) was an approved drug on the market in Europe. 
FDA, U.S. Food and Drug Administration.
Table 2. Commonly used anti-obesity medications
Drug Mechanism Effects on weight Adverse effects Status Comments
Medications for short-term weight management or selected medications used off-label to promote weight loss 
Phentermine
a Sympathomi-
metic amine 
(appetite  
suppressant)
3.6 kg placebo-sub-
tracted weight loss 
in studies ranging 
from 2-24 weeks
Insomnia, tremor, ↑ blood 
pressure and pulse rate, 
headache, palpitation, con-
stipation
Currently approved drug for 
short-term weight manage-
ment (≤12 weeks) in U.S., 
Korea and some countries, 
withdrawn 2000 in U.K. 
Diffusion con-
trolled release 
preparation is 
available
Diethylpropi-
on
a
As above 3.0 kg placebo-sub-
tracted weight loss 
in studies ranging 
from 6-52 weeks
As above Currently approved drug for 
short-term weight manage-
ment
Zonisamide
a Anti-convulsant 
agent
5.0% placebo-sub-
tracted weight loss 
at 12 weeks
↑ Nervousness, sweating, 
tremors, gastrointestinal ad-
verse effects, hypersomnia, 
fatigue, and insomnia
Used off-label No enough clinical 
trials; should not 
exceed 400 mg/
day
Topiramate
a  As above 6.5% placebo-sub-
tracted weight loss 
at 24 weeks
Paresthesia, dizziness, altered 
taste, fatigue, memory im-
pairment, somnolence, an-
orexia, and abdominal pain
Used off-label Associated with 
teratogenicity; 
should not ex-
ceed 400 mg/day 
Medication for long-term weight management
Orlistat
a Pancreatic  
lipase inhibitor 
2.9 kg placebo-sub-
tracted weight loss 
at 1 year
Abdominal pain, bloating, 
flatulence, oily stools, diar-
rhea, ↓ absorption of fat sol-
uble vitamins
Only approved drug for long-
term weight management
Available over-the-
counter in several 
countries
Modified from Vetter et al. Nat Rev Endocrinol 2010;6:578-88 [12].
↑, increased; ↓, decreased.
aData from Li et al. Ann Intern Med 2005;142:532-46 [13].15
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evaluated in the management of obesity, which often requires 
continuous treatment to achieve and maintain weight loss, 
though the rigidity of a regulatory committee for the approval 
of novel anti-obesity drugs and the regulatory guidelines for 
anti-obesity therapy represent a significant limitation to devel-
oping drugs. The present paper reviews the effects and safety 
of the medications which are available for the treatment of 
obesity including many recently withdrawn from the market, 
and discusses several newer treatments currently being inves-
tigated. 
SYMPATHOMIMETIC DRUGS
Phentermine 
Phentermine is one of the centrally acting appetite-suppressant 
drugs of the β-phenethylamine family, which was approved for 
short-term (up to 3 months) use in the treatment of obesity by 
the U.S. FDA in 1959 and remains available today. There is lit-
tle data from large randomized controlled trials (RCTs) relat-
ing to the long-term efficacy or safety of phentermine, especial-
ly when used as monotherapy. The β-phenethylamine family 
drugs have limited use in the routine management of obesity 
and are not currently approved for long-term use. A study in 
1968 was the only longer-term (36 weeks) controlled trial of 
phentermine and demonstrated a mean weight loss of 12.2 kg 
with phentermine compared to 4.8 kg with a placebo (P<0.001). 
A meta-analysis, which included 6 randomized trials lasting 
from 2 to 24 weeks, reported patients treated with phentermine 
lost an average of 3.6 kg of additional weight compared with a 
placebo [14]. There have been no new RCTs of phentermine 
since 1999, and our research team recently reported the effica-
cy and safety of a newly developed formulation of phentermine 
diffuse-controlled release (DCR) in obese Korean patients [15]. 
This was a randomized, double-blind, placebo-controlled trial 
of 12 weeks treatment with phentermine DCR 30 mg (n=37) 
or placebo (n=37) once daily in obese patients with controlled 
diabetes, hypertension, or dyslipidemia. The participants in 
the phentermine DCR group showed significant reductions in 
body weight (-9.3±3.4 kg vs. -1.8±3.1 kg, P<0.001) and waist 
circumference (7.2±0.5 cm vs. 2.1±0.6 cm, P<0.001) com-
pared with the placebo group. Weight reductions of 5% or 
greater from the baseline (95.8% vs. 20.8%, P<0.001) and 10% 
or more (62.5% vs. 4.7%, P<0.001) were shown in the phen-
termine DCR group. Total cholesterol and low density lipo-
protein cholesterol (LDL-C) levels were significantly improved 
in the phentermine DCR group. However, there were no sig-
nificant differences in systolic and diastolic blood pressure be-
tween the groups, and pulse rate in the phentermine DCR 
group significantly increased compared with the placebo group 
(P=0.02). Dry mouth and insomnia were the most common 
adverse events, but were mild to moderate and transient. Al-
though the long-term effects and safety of the new formula-
tion of phentermine DCR cannot be evaluated because of Ko-
rea FDA regulations, short-term phentermine DCR treatment 
resulted in significant reduction of weight and improvement 
of metabolic parameters, including waist circumference and 
several lipid profiles, without clinically severe adverse events.
  The authors of the present study did not identify any sys-
tematic reports of adverse events with phentermine [15]. How-
ever, because phentermine has sympathomimetic properties, 
possible side effects such as insomnia, dry mouth, dizziness, 
palpitation, hand tremor, and elevation in blood pressure and 
pulse rate should be considered. Although no serious adverse 
events were reported in the meta-analysis of RCTs on the use 
of phentermine for weight loss [14], the upper limit of the 
1-sided 95% confidence interval [CI] given the number of pa-
tients studied who received phentermine was 1.5%, meaning 
the rate of serious adverse events could be as high as 15 per 
1,000 [13]. Sympathomimetic drugs are also scheduled by the 
U.S. Drug Enforcement Agency, suggesting the government’s 
view the drugs may be abused. If health professionals decide 
to use any of these drugs, physicians should monitor blood 
pressure and heart rate regularly to ensure acceptable levels are 
maintained in patients receiving phentermine.
  Phentermine had been used in combination with fenflura-
mine. The combination therapy demonstrated significantly 
more weight loss than a placebo in a 28-week RCT (15.5% vs. 
4.9%, P<0.001). However, fenfluramine was withdrawn from 
the market by the U.S. FDA in 1997 [10]. A preliminary report 
identified heart valve damage and pulmonary arterial hyper-
tension in association with the use of fenfluramine [6]. Phen-
termine is currently under evaluation in combination with 
topiramate (see section below entitled “Combination treat-
ments being developed”).
Diethylpropion
Another amphetamine-like analogue, diethylpropion, is a 
phenylethylamine ring compound with minor sympathomi-
metic properties and with fewer stimulant effects than am-
phetamine. Although diethylpropion has been approved by 16
Kang JG, et al.
Diabetes Metab J 2012;36:13-25 http://e-dmj.org
the U.S. FDA for treatment of obesity since 1959, diethylpro-
pion has been used off-label to achieve modest weight loss, 
and few studies have evaluated the long-term use of diethyl-
propion [7]. A meta-analysis that assessed the use of diethyl-
propion for weight loss in obese individuals identified 13 stud-
ies published between 1965 and 1983. Although most studies 
were less than 20 weeks, the duration of treatment with dieth-
ylpropion varied from 6 to 52 weeks, and obese patients treat-
ed with diethylpropion lost an average of 3.0 kg of additional 
weight compared with a placebo [14]. 
  No new phentermine’s RCTs have been conducted since 
1983, but a recent report evaluates the efficacy of diethylpropi-
on on a long-term basis, with an emphasis on cardiovascular 
and psychiatric safety aspects [16]. Sixty-nine obese healthy 
adults received a hypocaloric diet and were randomized to di-
ethylpropion 50 mg twice daily or placebo for 6 months. After 
this period, all participants received diethylpropion in an open-
label extension for an additional 6 months. After the initial 6 
months, the diethylpropion group lost an average of 9.8% of 
initial body weight vs. 3.2% in the placebo group (P<0.0001). 
From baseline to month 12, the mean weight loss produced by 
diethylpropion was 10.6%. Participants in the placebo group 
who were switched to diethylpropion after 6 months lost an 
average of 7.0% of initial body weight. No differences in blood 
pressure, pulse rate, electrocardiogram, and psychiatric evalu-
ation were observed. Dry mouth and insomnia were the most 
frequent adverse events, which were experienced in the first 3 
months and became less apparent with continued treatment. 
  Common side effects of diethylpropion included insomnia, 
dry mouth, dizziness, headache, mild increases in blood pres-
sure, palpitations and rash, which are similar to the pharma-
cologic effect of amphetamines. Diethylpropion and phenter-
mine are classified by the U.S. Drug Enforcement Agency as 
schedule IV drugs, meaning they have a very low potential for 
drug abuse. Although no serious adverse events were reported 
in the RCTs of diethylpropion, the upper limit of the 1-sided 
95% CI given the number of patients studied who received di-
ethylpropion was 1.5%, meaning the rate of serious adverse 
events could be as high as 15 per 1,000 [13]. 
CANNABINOID-1 RECEPTORS 
ANTAGONISTS (RIMONABANT AND 
TARANABANT)
The endocannabinoid system has been identified as playing a 
significant role in the control of appetite as well as glucose me-
tabolism [17]. Rimonabant was the first in a new class of agents 
that appears to work by selectively blocking the cannabinoid-1 
receptors in the endocannabinoid system and has been exten-
sively investigated in the Rimonabant in Obesity (RIO) pro-
gram, comprised of 4 randomized, double-blinded, placebo-
controlled phase 3 clinical trials recruiting more than 6,000 
overweight or obese patients whose weight at the start of the 
studies was on average 94 to 104 kg [18-21]. Each of the 4 
studies on rimonabant showed significant reductions in body 
weight and waist circumference over a 1 to 2-year period. 
Rimonabant also improved cardiometabolic risk factors, in-
cluding triglycerides, blood pressure, insulin resistance, C-re-
active protein levels, and high density lipoprotein cholesterol 
concentrations in both non-diabetic and type 2 diabetic over-
weight/obese patients. Rimonabant was generally well-tolerat-
ed. However, later reports showed the use of rimonabant was 
associated with psychiatric side effects, including anxiety, de-
pression, and suicidal ideation. The adverse psychiatric events 
were observed in 26% of the participants in the rimonabant 
group compared with 14% in the placebo group in the same 4 
studies [22], and the risk of depressive symptoms was estimat-
ed at 2.5 fold higher than in placebo-treated patients [8]. In 
spite of the extensive favorable clinical data, the U.S. FDA re-
fused marketing authorization for rimonabant as a conse-
quence of the risks. Rimonabant was marketed in 18 EU mem-
ber states. However, in November 2008, the EMA subsequently 
withdrew authorization for rimonabant in Europe.
  Taranabant, a second CB1 antagonist, has also been assessed 
in large scale clinical trials over a 52-week period and showed 
4 kg placebo-adjusted significant weight reduction, similar to 
rimonabant [23]. However, psychiatric side effects were ob-
served in all studies with taranabant using both high [23,24] 
and low doses [25]. For this reason, psychiatric side effects are 
considered a class issue for first generation CB1 antagonists. 
As a consequence, the development of other first generation 
CB1 antagonists, including the Pfizer CB1 antagonist, oten-
abant (CP-945,598), and the Bristol Myers Squibb compound, 
SLV-319, have also been halted.
SIBUTRAMINE
Sibutramine, a selective noradrenaline/serotonin reuptake in-
hibitor, was widely used after approval by the U.S FDA in 1997. 
In meta-analyses that included obese participants treated with 17
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sibutramine for at least 12 months, the mean placebo subtract-
ed weight loss was 4.2 to 4.45 kg [26]. Among Korean obese 
patients receiving sibutramine, 68.2% of patients lost 5% or 
more of body weight compared with 13.0% in the placebo 
group with the mean absolute weight change of -5.9±3.8 kg in 
the sibutramine group and -1.6±2.6 kg in the placebo group 
after 12 weeks of treatment [27]. 
  Because sibutramine led to a 4.5% body weight loss for 
long-term treatment (over 24 to 52 weeks) [13] and also 
showed potential benefits by improving cardiometabolic fac-
tors including plasma glucose, insulin, and lipid-profiles [28], 
sibutramine was the most effective anti-obesity drug market-
ed, though in a meta-analysis which included 10 studies of ap-
proximately 1,213 participants who were treated with sibutra-
mine or placebo for at least 6 to 12 months, treatment was not 
associated with a significant decrease in total cholesterol after 
adjustment for weight loss [29]. 
  Sibutramine was relatively well tolerated because common 
side effects included only constipation, headache, dry mouth, 
and insomnia. However, sibutramine was originally reviewed 
by the EMA in 1999 and 2002, following concerns over its safe-
ty, particularly cardiovascular side effects (increased blood 
pressure and heart rate), and was temporarily withdrawn from 
the Italian market on the basis of 47 adverse event reports (ar-
rhythmias, primarily tachycardia, and hypertension) and 2 
deaths from cardiovascular disease causes in that country [30]. 
At that time, the Agency’s Committee for Medicinal Products 
for Human Use (CHMP) concluded the benefits of sibutra-
mine for the management of obese and overweight patients 
outweighed the risks. However, the CHMP also requested Ab-
bott Laboratories start a long-term study of sibutramine in pa-
tients with cardiovascular risk factors, with particular focus on 
the medicine’s safety.
  The 5-year Sibutramine Cardiovascular Outcomes (SCOUT) 
trial was a randomized, double-blind, placebo-controlled study 
involving 10,742 overweight or obese patients with cardiovas-
cular disease, hypertension, or type 2 diabetes [31]. After a 
6-week lead-in period, patients who received single-blind 
sibutramine had on average a 2.2 kg reduction of body weight, 
a 2.0 cm reduction of waist circumference, a 3.0 mm Hg de-
crease in systolic blood pressure, a 1.0 mm Hg decrease in dia-
stolic blood pressure, and a 1.5 mm Hg decrease in pulse rate. 
In addition, sibutramine was found to be efficacious, tolerable, 
and safe in the 6-week single-blind period. In January 2010, a 
preliminary report of the SCOUT study, which showed sibutra-
mine was associated with an increased risk of serious, nonfatal 
cardiovascular events such as myocardial infarction or stroke 
as compared with a placebo (11.4% vs. 10%; hazard ratio [HR], 
1.16; 95% CI, 1.03 to 1.31), led to the recommendation to sus-
pend the use of sibutramine by the CHMP of the EMA. 
Sibutramine has been subsequently withdrawn from the Euro-
pean market. The U.S. FDA requested healthcare professionals 
be notified sibutramine should not be used in patients with 
known cardiovascular disease. The full results of the SCOUT 
study were published in September 2010 [11]. Long-term 
sibutramine treatment was shown to increase the risk of non-
fatal myocardial infarction and nonfatal stroke, but not of car-
diovascular death or death from any cause in overweight or 
obese patients with pre-existing cardiovascular diseases. The 
U.S. FDA initially allowed sibutramine to be available and re-
viewed its potential benefits and risks [32], but asked for stron-
ger warnings on the product labels. The warning recommend-
ed sibutramine not be used by people with a history of stroke 
or heart attacks and uncontrolled high blood pressure. A 3-year 
prospective observational study of 15,686 patients who were 
prescribed sibutramine in New Zealand has not demonstrated 
a higher risk of death from a cardiovascular event [33]. How-
ever, the U.S. FDA decided the drug may pose unnecessary 
cardiovascular risks to patients, and thus sibutramine was 
withdrawn on October 8, 2010.
ORLISTAT
Orlistat is a potent and reversible gastrointestinal lipase inhibi-
tor preventing dietary fat absorption by 30% by inhibiting 
pancreatic and gastric lipase. Orlistat was approved in 1998 
and is currently the only available drug for the long-term man-
agement of obesity. The prescribed dose is 120 mg capsule 3 
times daily, and a half dose (60 mg) is available over-the-coun-
ter in some countries, including the U.S. The efficacy of orlistat 
for weight loss has been reported in several RCTs for the long-
term management of obesity (approximately 4 years) [34,35]. 
In meta-analyses of 12 and 15 trials, the mean difference in 
weight loss due to orlistat was -2.59 kg (95% CI, -3.46 to -1.74 
kg) at 6 months and -2.9 kg (-3.2 to -2.5 kg) at 12 months [13], 
which was more than the placebo. The beneficial effect on body 
weight is sufficient to improve several cardiometabolic param-
eters, including waist circumference, blood pressure, blood 
glucose levels, and lipid profiles [35,36]. In a meta-analysis 
which included 15 studies of approximately 10,995 partici-18
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pants who were treated with orlistat or placebo for at least 6 to 
12 months, treatment with orlistat was associated with a sig-
nificant decrease in total cholesterol after adjustment for weight 
loss [29], which indicates orlistat is a useful adjunctive tool for 
improving cardiovascular risk factor profiles in obese patients. 
Orlistat also reduced the incidence of type 2 diabetes from 
9.0% to 6.2% (HR, 0.63; 95% CI, 0.46 to 0.86) in a longer 4-year 
trial [35]. 
  Among Korean obese patients receiving orlistat for 24 weeks, 
the mean weight change from baseline was -2.8 kg. Treatment 
with orlistat also improved several metabolic parameters. There 
were significant improvements of glycemic control (HbA1c, 
-0.87%; P<0.01), fasting insulin, total cholesterol, LDL-C (P<
0.001), waist circumference (-5.48±0.54 cm, P<0.001), systol-
ic blood pressure and diastolic blood pressure (P=0.000), with-
out serious side effects [37].
  The most common side effects of orlistat are gastrointestinal 
and include diarrhea, fecal incontinence, oily spotting, flatu-
lence, bloating, and dyspepsia [10,26,38]. As a result of the ad-
verse effects, orlistat may not be well tolerated. However, the 
side effects tend to occur early and can be reduced as patients 
learn how to avoid fat-rich diets. 
  Recently, serious liver injury has been reported over the past 
10 years. Between 1999 and 2008, the U.S. FDA received 32 re-
ports of severe liver injury, including 6 cases of liver failure in 
patients using orlistat, which prompted the U.S. FDA to un-
dertake a review of orlistat’s treatment safety. The review iden-
tified a total of 13 cases of severe liver injury, reported between 
April 1999 and August 2009 out of an estimated 40 million 
people worldwide who had used Xenical or Alli. The U.S. FDA 
advised healthcare professionals to continue prescription of 
orlistat in August 2009, because severe liver injury was rare. 
However, a review in May 2010 led to a label revision and the 
addition of a warning of severe liver injury to educate the pub-
lic regarding the signs and symptoms of liver injury.
MONOTHERAPY AND COMBINATION 
THERAPIES CURRENTLY UNDER 
INVESTIGATION
Lorcaserin
Lorcaserin is a selective serotonin 2C (5-HT2C) receptor ago-
nist that reduces body weight by reducing food intake and is 
not thought to stimulate the 5-HT2B receptor associated with 
cardiac valvulopathy. Nonselective serotoninergic agents, in-
cluding fenfluramine and dexfenfluramine, were withdrawn 
form the market in 1997 after they were reported to be associ-
ated with valvular heart disease [6].
  Two phase 3 studies have now been reported (Behavioral 
Modification and Lorcaserin for Overweight and Obesity 
Management [BLOOM] [39] and BLOSSOM [40]) and have 
shown a modest but significant placebo-adjusted weight re-
duction. In a 2-year, double-blind, placebo-controlled study, 
3,182 obese and overweight patients who were treated with 
placebo or lorcaserin 10 mg/kg twice daily, obese patients lost 
3.6 kg (3.6% body weight) more than controls at the end of the 
first year. Additionally, the weight reduction was maintained 
in more patients who continued to receive lorcaserin during 
year 2 (67.9%) than in patients who received a placebo during 
year 2 (50.3%, P<0.001), among the patients who received lor-
caserin during year 1 and who had lost 5% or more of their 
baseline weight at 1 year [39]. A second trial of similar design 
over 1 year, termed “BLOSSOM” in which 4,008 patients were 
treated with lorcaserin 10 mg every day or twice daily, was de-
signed to assess the efficacy and safety of a dose range of lorca-
serin when administered in conjunction with a nutritional and 
physical exercise program to promote weight loss in obese pa-
tients and at-risk overweight patients. The participants who 
took lorcaserin 10 mg twice daily achieved an average weight 
loss of 5.9% of their body weight, compared to 2.8% with a 
placebo (P<0.0001). Similarly, patients who took lorcaserin 10 
mg once daily achieved an average weight loss of 4.8% of their 
body weight at the end of 12 months (P<0.0001) [40]. The most 
frequent adverse events in the 2 phase 3 studies were fatigue, 
headache, dizziness, dry mouth, and nausea, which were not 
significantly different between treatment groups. In addition, 
there was no increase in the rate of cardiac valve disease after a 
2-year treatment with lorcaserin [39]. As a result of the trials, a 
new drug application (NDA) for lorcaserin was filed with the 
U.S. FDA in December 2009. However, the advisors recom-
mended against approval in September 2010, as they did not 
conclude the potential benefits of the drug outweighed the 
risks [41]. Arena Pharmaceuticals Inc. (San Diego, CA, USA) 
reported results from a third phase 3 clinical trial for lorcaser-
in, Behavioral Modification and Lorcaserin for Overweight 
and Obesity Management in Diabetes Mellitus (BLOOM-DM), 
which evaluated the safety and efficacy of lorcaserin for weight 
management in obese and overweight patients with type 2 dia-
betes and planned to submit the final study report from the 
BLOOM-DM trial as a supplement to the NDA for lorcaserin 19
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to the U.S. FDA [42]. The BLOOM-DM study evaluated 604 
obese and overweight patients with type 2 diabetes. Patients 
were randomized to lorcaserin 10 mg twice daily (n=256), 
lorcaserin 10 mg dosed once daily (QD) (n=95) or placebo 
(n=253). To expedite enrollment, randomization to the lorca-
serin 10 mg once daily dose was discontinued after approxi-
mately 300 patients were enrolled in the trial. The 3 primary 
efficacy endpoints at week 52 were as follows: the proportion 
of patients who lost at least 5% of their baseline body weight, 
change from baseline in body weight, and the proportion of 
patients who lost at least 10% of their baseline body weight. 
Using Modified Intent-to-Treat Last Observation Carried For-
ward (MITT-LOCF) analysis, lorcaserin 10 mg twice daily met 
the 3 primary efficacy endpoints by producing statistically sig-
nificant weight loss compared to placebo (P<0.0001). At week 
52, 37.5% of patients treated with lorcaserin 10 mg twice daily 
achieved at least 5% weight loss, more than double the 16.1% 
of patients taking a placebo. Patients treated with lorcaserin 10 
mg twice daily achieved a mean weight loss of 4.5% (4.7 kg), 
compared to 1.5% (1.6 kg) with the placebo. Additionally, at 
week 52, 16.3% of lorcaserin 10 mg twice daily patients 
achieved at least 10% weight loss compared to 4.4% of patients 
taking a placebo. BLOOM-DM also evaluated multiple sec-
ondary endpoints at week 52. Five families of endpoints have 
been or are being evaluated: glycemic, lipid, blood pressure, 
body composition, and quality of life (QOL). Data from the 
first 3 families are available and analysis of body composition 
and QOL are pending. Within the glycemic, lipid and blood 
pressure families, lorcaserin patients achieved statistically sig-
nificant improvements relative to placebo in HbA1c and fast-
ing glucose. Lorcaserin 10 mg twice daily patients achieved a 
0.9% reduction in HbA1c, compared to a 0.4% reduction for 
the placebo group (P<0.0001). However, the FDA did not ap-
prove the application for lorcaserin due to unexplained pre-
clinical carcinogenicity signals in rats, specifically, an increase 
in breast tumors. In January 2012, Arena Pharmaceuticals 
submitted a response to the Complete Response Letter issued 
by the FDA following review of the lorcaserin NDA and the 
company expects by the end of January, the FDA will confirm 
acceptance of the response and assign a new Prescription Drug 
User Fee Act (PDUFA) date.
Glucagon-like peptide-1 (GLP-1) analogues
Anorexigenic GLP-1 are gut hormones that increase secretion 
of insulin in pancreatic β-cells. GPL-1 analogues such as ex-
enatide and liraglutide are approved for the treatment of type 
2 diabetes, and the long-term use of the GLP-1 analogues leads 
to a decrease in HbA1c level and blood pressure [43,44]. Me-
ta-analysis of clinical trials also revealed an average weight loss 
of 2.13 kg in exenatide-treated groups more than the placebo, 
and a 4.76 kg weight loss compared with insulin [45]. Exena-
tide is currently only in phase 2 trials for obesity [46]. A recent 
32-week open-label extension study of liraglutide in 564 non-
diabetic obese patients following the 20 week dose-ranging 
placebo-controlled phase 2 study of liraglutide in comparison 
with orlistat treatment (a mean weight loss of approximately 
6.0 kg with liraglutide compared with 2.8 kg with a placebo 
and 4.1 kg with orlistat) [47] demonstrated that high-dose lira-
glutide led to a 5.5 to 6.0 kg placebo-adjusted weight loss at 52 
weeks [48]. Novo Nordisk plans to initiate additional phase 3 
trials of liraglutide for anti-obesity treatment in 2011.
Tesofensine 
Tesofensine is an inhibitor of noradrenaline, dopamine and 
serotonin reuptake that reportedly also indirectly stimulates 
the cholinergic system and a sympathomimetic in the family 
of sibutramine. The drug was initially developed for the treat-
ment of Parkinson’s disease or Alzheimer’s disease. Although 
its efficacy was limited for this application, significant weight 
loss was evident [49]. A proof of concept phase 2 study, a 24-
week randomized double-blind placebo-controlled study, 
showed the proportion of patients achieving ≥5 kg (4.9%) was 
59%, 87%, and 91% for 0.25, 0.5, and 1 mg groups, respective-
ly, compared with 29% of controls. However, heart rate was 
significantly elevated in all tesofensine groups, and the highest 
dose of tesofensine (1 mg daily) showed a significant increase 
in blood pressure and the highest frequency of mood change 
[50]. Reportedly, the phase 3 program agreed with the FDA 
which assessed the 0.5 and 0.25 mg dose levels only [51]. Giv-
en the results, further phase 3 trials may limit the dose to 0.25 
and 0.5 mg in order to reduce the impact on heart rate and 
blood pressure. NeuroSearch plans to initiate a clinical phase 3 
program endorsed by the FDA and EMA. The trial consists of 
3 trials: 2 traditional 1-year obesity trials with a mixed popula-
tion with and without co-morbidities such as type 2 diabetes 
and dyslipidemia and 1 cardiovascular outcome study with 
more than 2 years of treatment in patients with a history of 
cardiovascular disease. The cardiovascular study is planned to 
enroll approximately 6,000 patients.20
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Cetilistat
Cetilistat is an inhibitor of pancreatic lipase, an enzyme that 
breaks down triglycerides in the intestine. Without this en-
zyme, triglycerides from the diet are prevented from being hy-
drolyzed into absorbable free fatty acids and are left to be ex-
creted undigested. This drug, while similar to the currently 
FDA-approved drug orlistat, may have a more tolerable side-
effect profile due to a different molecular structure. A phase 2 
trial studied 612 obese, diabetic subjects with a BMI of 28 to 
45 kg/m
2 over a 12-week treatment period. Cetilistat 80 and 
120 mg promoted significant weight loss compared with pla-
cebo (3.85 kg and 4.32 kg vs. 2.86 kg, respectively). Cetilistat-
induced weight loss was similar to the weight loss achieved 
with orlistat (3.78 kg). Cetilistat was well tolerated and showed 
fewer discontinuations due to adverse events than in the pla-
cebo and orlistat groups. Given that discontinuation in the or-
listat group was significantly worse than in the 120 mg cetili-
stat and placebo groups, and was entirely due to gastrointesti-
nal adverse events, cetilistat may become a preferred lipase in-
hibitor for achieving weight loss [52]. Phase 3 trials of cetilistat 
are currently in progress in Japan.
Combination treatments being developed
Combination treatments of anti-obesity drugs showed disap-
pointing results. The first important clinical study for weight 
reduction combining drugs used phentermine and fenflura-
mine as previously mentioned. The trial showed a highly sig-
nificant weight reduction. However, fenfluramine was with-
drawn from the market worldwide on September 15, 1997, be-
cause of heart valve damage [6]. Combination treatment of or-
listat and sibutramine, which had been approved only for long-
term use, did not induce any further weight loss [53]. Because 
none of the single-agent drugs that have been approved or ap-
pear close to approval have consistently been able to achieve a 
weight loss of more than approximately 10% of body weight 
[54], several other combinations of existing drugs are now un-
der development and may be the next therapeutic option for 
treatment of obesity.
  Qnexa (Vivus Pharmaceuticals, Mountain View, CA, USA), 
a combination of low-dose phentermine and the antiepileptic 
agent topiramate, has recently been shown to be effective for 
the long-term treatment of obesity, though topiramate remains 
unlicensed for obesity. The efficacy and safety of this combina-
tion drug as a treatment for obesity was recently evaluated in 3 
phase 3 trials (EQUATE, EQUIP, CONQUER) [55,56] in over 
4,500 obese patients and the U.S FDA acknowledged the effect 
of weight reduction. However, In October 2010, the FDA did 
not approve Qnexa and requested more evidence that the ele-
vated heart rate does not increase cardiovascular risk. In addi-
tion, Vivus Pharmaceuticals had concerns regarding the drug’s 
teratogenic potential. In January 2011, the agency announced 
the FDA had requested additional information regarding tera-
togenicity and the FDA’s endocrinologic and metabolic drugs 
advisory committee is scheduled to review the NDA for Qnexa 
for the treatment of obesity in February 2012. The company 
resubmitted the NDA on October 2011 seeking approval to 
market Qnexa in the U.S. and the FDA accepted the NDA for 
review in November 2011. The target date for the FDA to com-
plete review of the Qnexa NDA is April 2012.
  Contrave (Orexigen Pharmaceuticals, La Jolla, CA, USA) is 
a fixed-dose combination of naltrexone sustained-release (SR) 
and bupropion SR. Bupropion, a dopamine and norepineph-
rine reuptake inhibitor was approved for depression and smok-
ing cessation and showed modest weight loss. Naltrexone, ap-
proved for the treatment of opioid addiction and alcoholism, 
is not associated with weight reduction. However, the combi-
nation with bupropion and naltrexone leads to a synergistic 
effect on weight control, although the mechanism by which 
the naltrexone/bupropion combination induces weight loss is 
not entirely understood. Several phase 3 trials (COR, COR-
BMOD, and COR-Diabetes) have been completed to evaluate 
this combination in both diabetic and non-diabetic obese pa-
tients [57-59]. 
  The Contrave group showed significant weight reduction 
and improvement in cardiometabolic markers compared to 
the placebo group in all studies. The COR-Diabetes trial showed 
overweight or obese patients with type 2 diabetes lost signifi-
cantly more weight and achieved greater improvement in gly-
cemic control than patients treated with a placebo after 56 
weeks. The Contrave group lost significantly more weight (5.0% 
vs. 1.8%, P<0.001) at 56 weeks in 44.5% of patients (≥5% loss 
of body weight) compared to 18.9% using the placebo. Base-
line A1C, the standard test for monitoring glycemic control, 
was significantly reduced by 0.6% with Contrave compared to 
0.1% with the placebo [57]. A specific 56-week, randomized, 
placebo-controlled trial examined the efficacy and safety of 
naltrexone plus bupropion as an adjunct to intensive behavior 
modification (BMOD) in obese and overweight patients with 
major depressive illness because of recent concerns regarding 
psychiatric side effect issues and the known potential for bu-21
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propion to induce a depressive mood. The study concluded 
Contrave significantly improved body weight and ameliorated 
depressive symptoms as scored by the MADRS [58]. Contrave 
was submitted for U.S. regulatory approval in March 2010. The 
original submission was based on multiple clinical trials that 
evaluated Contrave in more than 4,500 patients. However, the 
U.S. FDA rejected Contrave in January 31, 2011 due to con-
cerns regarding the cardiovascular safety profile of naltrexone/
bupropion when used long-term in a population of over-
weight and obese subjects [8]. 
SUMMARY
Obesity can be an incurable chronic disease that increases the 
risk for cardiovascular diseases such as diabetes and hyperten-
sion. Because lifestyle interventions alone rarely result in long-
term weight loss and the large proportion of patients return to 
baseline weight within 3 to 5 years, pharmacotherapy as a life-
style modification adjunct to improve the induction and main-
tenance of weight loss may be considered for individuals with 
a BMI ≥30 kg/m
2 or for individuals with a BMI ≥27 kg/m
2 
and co-morbidities [4]. Early administration of anti-obesity 
pharmacotherapy could provide significant benefit in the re-
duction of both weight and the risk for the development of co-
morbidities. However, despite promising results on reduction 
of body weight and improvement of several cardio-metabolic 
factors, many drugs that have been effective weight loss medi-
cations were withdrawn from the market in the last few years 
due to serious adverse effects. The positive data observed for 
surrogate markers was found not necessarily corresponding to 
positive clinical outcomes, though the anti-obesity drugs were 
expected to reduce cardiovascular outcome, beyond weight 
control. Treatments that reduce weight but do not improve 
cardiovascular outcome are thought to be of cosmetic benefit 
Table 3. Monotherapies and combination therapies currently under investigation
Drug Mechanism Expected  
weight loss Adverse effects Status Comments
Monotherapy
Lorcaserin
a  Highly selective 
5HT-2C receptor 
agonist 
Drug: 8.2 kg  
Placebo: 3.4 kg
Headache, depression, infec-
tion, nausea and dizziness 
(Possible concerns of the ef-
fect on valvular dysfunction)
Not approval in 2010 
due to concerns over 
carcinogenicity ob-
served in animal 
Resubmitted the NDA 
on January, 2012
liraglutide
a  GLP-1 analogues Drug: 7.2 kg  
Placebo: 2.8 kg
Nausea, and increased risks of 
thyroid C-cell focal hyper-
plasia and medullary thyroid 
tumor in rats and mice
Phase 3 Approved in 2009 as a 
treatment for type 2 
diabetes
Tesofensine
a  Anti-convulsant 
agent 
Drug: 11.2 kg  
Placebo: 2 kg
Nausea, dry mouth, headache, 
insomnia, diarrhea and con-
stipation
Phase 3
Cetilistat
a  As above Drug: 4.3 kg  
Placebo: 2.8 kg
Abdominal pain, fecal urgency 
and diarrhea
Phase 3
Combination therapy
Qnexa
a (phen-
termine and 
topiramate) 
Sympathomimetic 
amine and anti-
convulsant agent 
Drug: 14.7 kg  
Placebo: 2.5 kg
Headache, paresthesia, dry 
mouth, paresthesias, dry 
mouth, nasopharyngitis and 
birth defects
Not approval in 2010 
due to concerns over 
teratogenic potential 
Resubmitted the NDA 
on October, 2011 and 
completed its review 
of the Qnexa on 
April, 2012 
Contrave
a (bu-
propion and 
naltrexone) 
Norepinephrine/
dopamine reup-
take inhibitor and 
opioid receptor 
antagonist 
Drug: 8.2 kg  
Placebo: 1.9 kg
Nausea, headache, insomnia, 
constipation
Not approval in 2011 
due to concerns over 
cardiovascular risks 
and psychological is-
sues 
Modified from Vetter et al. Nat Rev Endocrinol 2010;6:578-88 [12].
5HT-2C, 5-hydroxytryptamine 2C; NDA, new drug application; GLP-1, glucagon-like peptide 1. 
aData from Powell et al. Clin Pharmacol Ther 2011;90:40-51 [9].22
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only and would thereby be less likely to gain approval for clini-
cal use. Because orlistat is currently the only anti-obesity drug 
approved for long-term use, the development of new anti-obe-
sity drugs is therefore urgently needed. This reasoning has led 
to the development of a number of new treatments for obesity 
in which multiple mechanisms are targeted, either by a single 
drug, such as tesofensine, or through drug combinations such 
as Qnexa, Contrave and Empatic (Table 3). However, the pre-
vious withdrawals also suggest regulatory committees are in-
creasingly reluctant to approve a recommendation for the 
treatment of obesity using novel drugs, including lorcaserin, 
Qnexa, and Contrave without data that clearly supports long-
term safety. The emphasis that both the U.S. FDA and EMA 
have placed on metabolic indices is based on recognition the 
drugs impact the onset of cardiovascular outcome more di-
rectly than weight loss alone. Although the guidelines for ap-
proval and market withdrawal are considerable barriers to the 
development of new anti-obesity drugs, the long-term safety 
and efficacy of newly developed drugs should also be evaluat-
ed in the management of obesity, which often requires ongo-
ing therapy to achieve and maintain weight loss. Finally, gov-
ernment policy should support social intervention as a means 
of managing obesity because obese patients often return to 
toxic environments and behaviors. When considering anti-
obesity therapy, in addition to scientific and regulatory con-
siderations, patients’ financial barriers also need to be taken 
into account.
  In conclusion, it is expected that more effective and better 
tolerated anti-obesity drugs will be developed through a better 
understanding of the multiple mechanisms and complex physi-
ological systems targeting appetite. Additionally, a lifestyle 
modification will hopefully be supported alongside all other 
treatments for obesity, because it remains the cornerstone of 
the medical management of obesity. 
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